FDA Approves Neratinib for Extended Adjuvant Treatment of Breast Cancer

Share this content:
The FDA has approved neratinib for patients who initially received adjuvant trastuzumab-based therapy to treat HER2-overexpressed/amplified breast cancer.
The FDA has approved neratinib for patients who initially received adjuvant trastuzumab-based therapy to treat HER2-overexpressed/amplified breast cancer.

The US Food and Drug Administration (FDA) approved neratinib as an extended adjuvant treatment for patients who initially received adjuvant trastuzumab-based therapy to treat early-stage HER2-overexpressed/amplified breast cancer.1

The FDA based its approval on data from the double-blinded ExteNET Trial (ClinicalTrials.gov Identifier: NCT00878709), which randomly assigned 2840 women with early-stage disease who completed adjuvant trastuzumab within 2 years to receive placebo or neratinib for 1 year.

The primary efficacy outcome was invasive disease–free survival (iDFS).

Patients treated with neratinib had an iDFS of 94.2% vs 91.9% in patients who received placebo (hazard ratio [HR], 0.66; 95% CI, 0.49-0.90; P = .008) after 2 years.

The most frequently reported adverse event (AE) that led to discontinuation of therapy was diarrhea at 16.8%.

RELATED: BRCA 1/2 Status in Triple-negative Breast Cancer May Affect Responsiveness to Carboplatin

Other frequently observed AEs included nausea, vomiting, abdominal pain, fatigue, decreased appetite, stomatitis, dyspepsia, abdominal distension, and weight loss.

Reference

  1. FDA approves neratinib for extended adjuvant treatment of early stage HER2-positive breast cancer [press release]. Silver Spring, MD: US Food and Drug Administration; July 17, 2017.  https://www.fda.gov/Drugs/InformationOnDrugs/ ApprovedDrugs/ucm567259.htm. Accessed July 17, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters